CompletedNCT00287820
Five-month glucose and lipid effects of olanzapine or risperidone in schizophrenia
About this title
Read the official source — NCT00287820Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateFebruary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 46
- Sponsor
- Nathan Kline Institute for Psychiatric Research
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00287820
- Official title
Show the full official title
Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Nathan Kline Institute for Psychiatric Research, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine, olanzapine and risperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
